The trial is a multi-center, randomised, masked evaluation of nepafenac vs. placebo in 75 patients undergoing cataract surgery. The primary endpoint is to evaluate pain and the secondary endpoint is to evaluate inflammation following surgery. This planned interim analysis was conducted with approximately 50% of patients enrolled in the study.
Pain scores favored nepafenac over placebo at Day 1, Day 3, and Day 7 following surgery.
At Day 3, 71% of patients treated with nepafenac experienced No Pain versus 12% in the placebo arm. Post-operative inflammation, as determined by cell and flare scores, also favored the Nepafenac Evolute arm.
The treatment was generally well tolerated with no unexpected side effects reported.
Mati is developing the Evolute sustained ocular drug delivery platform, which Mati believes has the potential to treat a range of ocular indications.
The platform utilizes a device called a punctal plug, which is easily inserted into a patient's punctum. The device has already been approved to treat dry eye syndrome, but Mati is the first to conduct clinical trials in the US using punctal plugs as an anchoring device for a drug delivery platform.
A drug-eluting core is inserted into Mati's proprietary punctal plug, which allows medication to be continuously released into the tear film of the eye over a period of time.
Mati has completed multiple Phase II clinical trials using the Evolute platform, including multiple trials in glaucoma, ocular hypertension, and allergy patients.
The company's proprietary punctal plug design has demonstrated excellent lower punctum retention rates of 92% and 96% over a 12-week follow-up period in two separate multi-centre US clinical trials.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary